Home » Stocks » CKPT

Checkpoint Therapeutics, Inc. (CKPT)

Stock Price: $2.63 USD -0.03 (-1.13%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $2.68 +0.05 (1.90%) Jul 30, 7:49 PM
Market Cap 208.25M
Revenue (ttm) 165,000
Net Income (ttm) -26.31M
Shares Out 70.30M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.63
Previous Close $2.66
Change ($) -0.03
Change (%) -1.13%
Day's Open 2.61
Day's Range 2.57 - 2.66
Day's Volume 623,069
52-Week Range 1.90 - 5.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...

3 weeks ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: EQ, FLXN, RSLS
1 month ago - 24/7 Wall Street

One analyst becomes a fervent believer in the company's stock.

1 month ago - The Motley Fool

With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.

Other stocks mentioned: RIDE, RMD, HLX, HMPT, MS, OMCL, REGI ...
1 month ago - 24/7 Wall Street

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the completion of en...

2 months ago - GlobeNewsWire

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other stocks mentioned: BTU, EARS, EBON
2 months ago - PennyStocks

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results fo...

2 months ago - GlobeNewsWire

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other stocks mentioned: AGRX, AQMS, CATB, HEPA, IFRX, LLNW
4 months ago - InvestorPlace

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results ...

4 months ago - GlobeNewsWire

Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology

5 months ago - GlobeNewsWire

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim res...

8 months ago - GlobeNewsWire

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, developm...

8 months ago - GlobeNewsWire

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announce...

10 months ago - GlobeNewsWire

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim ...

10 months ago - GlobeNewsWire

Following up on a prior interview on the status of its leading immunotherapy product candidate, cosibelimab, Benzinga spoke with Checkpoint Therapeutics President and CEO James Oliviero about the progre...

10 months ago - Benzinga

NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F. Oli...

11 months ago - GlobeNewsWire

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, develo...

11 months ago - GlobeNewsWire

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) --  Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that an abstract...

1 year ago - GlobeNewsWire

- U.S. patent protection through at least May 2038 - Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled

1 year ago - GlobeNewsWire

CKPT expects to submitt a BLA for cosibelimab in 2021.

1 year ago - Seeking Alpha

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that feedback fro...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of it...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is propos...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacoki...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, develop...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, develop...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, develop...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, develo...

1 year ago - GlobeNewsWire

Checkpoint Therapeutics, Inc. (CKPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 years ago - Zacks Investment Research

About CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2017
Stock Exchange
NASDAQ
Ticker Symbol
CKPT
Full Company Profile

Financial Performance

In 2020, CKPT's revenue was $1.07 million, a decrease of -37.41% compared to the previous year's $1.71 million. Losses were -$23.08 million, -6.61% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is 15.80, which is an increase of 500.76% from the latest price.

Price Target
$15.80
(500.76% upside)
Analyst Consensus: Strong Buy